Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGNNYSEARCA:MOON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGNApexigen$0.39$0.39$0.33▼$8.28$9.57M3.6967,731 shsN/AMOONDirexion Moonshot Innovators ETF MOON$10.33$10.33$8.57▼$14.95$22.52M2.0818,644 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGNApexigen0.00%0.00%0.00%0.00%0.00%MOONDirexion Moonshot Innovators ETF MOON0.00%0.00%0.00%0.00%+9.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGNApexigenN/AN/AN/AN/AN/AN/AN/AN/AMOONDirexion Moonshot Innovators ETF MOONN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGNApexigen 0.00N/AN/AN/AMOONDirexion Moonshot Innovators ETF MOON 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGNApexigenN/AN/AN/AN/A($0.09) per shareN/AMOONDirexion Moonshot Innovators ETF MOONN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGNApexigen-$32.07MN/A0.00∞N/AN/A-614.82%-133.30%N/AMOONDirexion Moonshot Innovators ETF MOONN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGNApexigenN/AN/AN/AN/AN/AMOONDirexion Moonshot Innovators ETF MOONN/A1.92%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGNApexigenN/A0.820.82MOONDirexion Moonshot Innovators ETF MOONN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGNApexigen13.65%MOONDirexion Moonshot Innovators ETF MOONN/AInsider OwnershipCompanyInsider OwnershipAPGNApexigen19.20%MOONDirexion Moonshot Innovators ETF MOONN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGNApexigen1124.86 million20.09 millionNot OptionableMOONDirexion Moonshot Innovators ETF MOONN/A2.18 millionN/ANot OptionableCURY, APGN, MOON, and HFD HeadlinesRecent News About These CompaniesBiden’s Cancer Moonshot’s Last Acts: Easing Pediatric Drug ShortagesOctober 28, 2024 | msn.comHSC Spinout CxPM Joins StartUp Health’s Alzheimer’s Moonshot CommunityOctober 25, 2024 | dallasinnovates.comDMoonshot Museum’s temporary exhibit allows people to see the future of moon researchOctober 11, 2024 | yahoo.comMoonshot R&D TOPOctober 5, 2024 | jst.go.jpJLuxembourg’s Moonshot: Leading the Global Eco-Digital TransitionOctober 4, 2024 | itnation.luI2022 Tech Innovators AwardsOctober 1, 2024 | crn.comCIntel’s Moonshot: Details From The Lunar Lake Launch EventSeptember 28, 2024 | forbes.comReport: Visionary Developers Plan ‘Moonshot’ Transformation of Bank of America Plaza in Downtown DallasSeptember 21, 2024 | dallasinnovates.comDA moonshot for the world’s oceansSeptember 19, 2024 | markets.businessinsider.comHCMT Direxion HCM Tactical Enhanced U.S. Equity Strategy ETFAugust 29, 2024 | seekingalpha.com'The fate of the moonshot is inextricably tied to Boeing's performance'August 28, 2024 | yahoo.comThe IT Services Firm on a Moonshot MissionAugust 27, 2024 | inc.comSEC Turns Down $SOL ETF Filings, Prompting Solana Holders to Shift to This Emerging AlternativeAugust 25, 2024 | techbullion.comTTech Sector Volatility Presents Opportunities With Direxion's Leveraged ETFsAugust 13, 2024 | msn.comDirexion's Inverse ETF SPDN Allows Investors To Profit From Market CarnageJuly 19, 2024 | msn.comLast Week in ETFs: Busy Week Welcomes 22 New ETFsJuly 1, 2024 | etftrends.comEFROM OIC: Options Market Innovation in FocusMay 2, 2024 | tradersmagazine.comTDirexion Moonshot Innovators ETF declares quarterly distribution of $0.0347March 21, 2024 | msn.com5 Best ETF Areas of Last WeekMarch 5, 2024 | zacks.comFDTX: Richly Priced Outperforming Growth StoryFebruary 20, 2024 | seekingalpha.comTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonAlphabet’s Comeback: The Hidden Engines Powering GoogleBy Ryan Hasson | June 23, 2025View Alphabet’s Comeback: The Hidden Engines Powering GoogleCURY, APGN, MOON, and HFD Company DescriptionsApexigen NASDAQ:APGNApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Direxion Moonshot Innovators ETF MOON NYSEARCA:MOON$10.33 0.00 (0.00%) As of 07/30/2024The Direxion Moonshot Innovators ETF (MOON) is an exchange-traded fund that is based on the S&P Kensho Moonshots index. The fund tracks a tier-weighted index that selects US-listed companies seeking innovative technologies. MOON was launched on Nov 12, 2020 and is managed by Direxion. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
